secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016670
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma gets FDA Fast Track for efzofitimod in pulmonary sarcoidosis
------------------------------------------------------------------------

- FDA granted Fast Track designation on August 9, 2022 for lead candidate efzofitimod.
- Fast Track aims to expedite development and review; may allow rolling submission.
- Pulmonary sarcoidosis is a major interstitial lung disease with no approved therapies.
- Efzofitimod is a novel immunomodulator targeting neuropilin-2; Phase 3 trial ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017022016670/0000950170-22-016670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017022016670/life-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer